Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Ji, Qingwei ^a,b   Lin, Yingzhong ^b   Liang, Zhishan ^c   Yu, Kunwu ^c   Liu, Yuyang ^a   Fang, Zhe ^a   Liu, Ling ^b   Shi, Ying ^b   Zeng, Qiutang ^c   Chang, Chao ^a   Chai, Meng ^a   Zhou, Yujie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute coronary syndrome; Adiponectin; Chemerin; Inflammation; Left ventricular function

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHEMERIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; BIOLOGICAL MARKER; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; SIGNAL PEPTIDE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENSINI SCORE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; AGED; BLOOD; HEART INFARCTION; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANGINA, STABLE; BIOMARKERS; CHEMOKINES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 84920850132     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0145-4     Document Type: Article

References (44)

1. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis where are we now? J Am Coll Cardiol 2013, 62:1541-1551.
2. Libby P: Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013, 368:2004-2013.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, et al: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
4. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000, 343:915-922.
5. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
6. Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN: Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013, 227:216-221.
7. Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA: Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease. Int J Endocrinol 2013, 2013:698567.
8. Asterholm IW, Rutkowski JM, Fujikawa T, Cho YR, Fukuda M, Tao C, Wang ZV, Gupta RK, Elmquist JK, Scherer PE: Elevated resistin levels induce central leptin resistance and increased atherosclerotic progression in mice. Diabetologia 2014, 57:1209-1218.
9. Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, Diao J, Wan Q, Cui X: Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones 2013, 18:643-652.
10. Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun X, Zhao X, Chen Y, Diao J, Zhang L: Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression. Cell Stress Chaperones 2014, 19:715-724.
11. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF: Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 2004, 4:166-170.
12. Liu SW, Qiao SB, Yuan JS, Liu DQ: Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf ) 2009, 71:202-207.
13. Basati G, Razavi AE, Abdi S, Sarrafzedegan N: Association of plasma leptin, homocysteine and nitric oxide levels with the presence and unstability of coronary artery disease. Biomark Med 2014, 8:405-412.
14. Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS: Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol 2013, 12:105.
15. van Stijn CM, Kim J, Barish GD, Tietge UJ, Tangirala RK: Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One 2014, 9:e86404.
16. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA, TIMI Study Group: Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J 2011, 161:1147-1155.
17. Cheng M, Hashmi S, Mao X, Zeng QT: Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol 2008, 24:385-390.
18. Rizk NM, El-Menyar A, Marei I, Sameer M, Musad T, Younis D, Farag F, Basem N, Al-Ali K, Al Suwaidi J: Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology 2013, 64:257-265.
19. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, Sawada T, Hirata K, Yokoyama M: Relation between plasma adiponectin, highsensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol 2008, 101:1-7.
20. Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S: Relationship of plasma adiponectin levels with acute coronary syndromes and coronary lesion severity in north Indian population. ISRN Cardiol 2013, 2013:854815.
21. Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon HM: Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines. Cardiovasc Diabetol 2013, 12:140.
22. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J: Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004, 90:528-533.
23. Zhang H, Mo X, Hao Y, Huang J, Lu X, Cao J, Gu D: Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. Am J Med Sci 2013, 345:455-461.
24. Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P: Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med 2010, 268:194-205.
25. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S: Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013, 42:1029-1039.
26. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA: Tazarotene-induced gene 2 (TIG2), a novel retinoidresponsive gene in skin. J Invest Dermatol 1997, 109:91-95.
27. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D: Specific recruitment of antigenpresenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003, 198:977-985.
28. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007, 282:28175-28188.
29. Roman AA, Parlee SD, Sinal CJ: Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 2012, 42:243-251.
30. Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y: A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun 2012, 423:152-157.
31. Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, Zhai Y, Wang W, Li X, Ning G: The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 2012, 41:281-288.
32. Xiaotao L, Xiaoxia Z, Yue X, Liye W: Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis 2012, 23:412-416.
33. Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, Chen L, Hong H: Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab 2012, 58:539-544.
34. Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M: Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis 2014, 235:256-262.
35. Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606.
36. Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DH, Yu HT, Kang E, Cha BS, Lee HC: Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012, 11:84.
37. Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, Libby P, Minami S: Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques. Atherosclerosis 2013, 226:373-377.
38. Venojärvi M, Wasenius N, Manderoos S, Heinonen OJ, Hernelahti M, Lindholm H, Surakka J, Lindström J, Aunola S, Atalay M, Eriksson JG: Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann Med 2013, 45:162-170.
39. Meric M, Soylu K, Avci B, Yuksel S, Gulel O, Yenercag M, Coksevim M, Uzun A: Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns. Med Sci Monit 2014, 20:698-705.
40. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf ) 2010, 72:342-348.
41. Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P: Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci 2014, 1:26-33.
42. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K: Adipocytokines in relation to cardiovascular disease. Metabolism 2013, 62:1513-1521.
43. Nakamura K, Fuster JJ, Walsh K: Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014, 63:250-259.
44. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H: Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol 2011, 10:87.